Zang A - Search Results

1

UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.

Yu Q, Zhang T, Xie C, Qiu H, Liu B, Huang L, Peng P, Feng J, Chen J, Zang A, Yuan X. Yu Q, et al. Among authors: zang a. Cancer Chemother Pharmacol. 2018 Jul;82(1):87-98. doi: 10.1007/s00280-018-3595-7. Epub 2018 May 4. Cancer Chemother Pharmacol. 2018. PMID: 29728798 Clinical Trial.

2

SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.

Huang L, Zhang T, Xie C, Liao X, Yu Q, Feng J, Ma H, Dai J, Li M, Chen J, Zang A, Wang Q, Ge S, Qin K, Cai J, Yuan X. Huang L, et al. Among authors: zang a. PLoS One. 2013 Oct 15;8(10):e77223. doi: 10.1371/journal.pone.0077223. eCollection 2013. PLoS One. 2013. PMID: 24143213 Free PMC article. Clinical Trial.

3

A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.

Li J, Yu Q, Fu S, Xu M, Zhang T, Xie C, Feng J, Chen J, Zang A, Cai Y, Fu Q, Liu S, Zhang M, Hong Q, Huang L, Yuan X. Li J, et al. Among authors: zang a. J Cancer Res Clin Oncol. 2016 Jul;142(7):1621-8. doi: 10.1007/s00432-016-2176-6. Epub 2016 May 9. J Cancer Res Clin Oncol. 2016. PMID: 27160286

4

Preablation neutrophil-to-lymphocyte ratio as an independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation.

Tan W, Sun W, Li X, Zhao L, Wang C, Zang A, Kong X. Tan W, et al. Among authors: zang a. J Cancer Res Ther. 2018 Jan;14(1):84-89. doi: 10.4103/jcrt.JCRT_835_17. J Cancer Res Ther. 2018. PMID: 29516965 Free article.

5

Multicenter clinical study for evaluation of efficacy and safety of transdermal fentanyl matrix patch in treatment of moderate to severe cancer pain in 474 chinese cancer patients.

Zhu YL, Song GH, Liu DQ, Zhang X, Liu KF, Zang AH, Cheng Y, Cao GC, Liang J, Ma XZ, Ding X, Wang B, Li WL, Hu ZW, Feng G, Huang JJ, Zheng X, Jiao SC, Wu R, Ren J. Zhu YL, et al. Chin J Cancer Res. 2011 Dec;23(4):317-22. doi: 10.1007/s11670-011-0317-7. Chin J Cancer Res. 2011. PMID: 23359267 Free PMC article.

6

Giant broad ligament leiomyoma with postoperative infection diagnosed with contrast-enhanced ultrasound: Case report and literature review.

Guo L, Wang MZ, Wang LJ, Zang AH, Jia DM, Hou L, Zhang P. Guo L, et al. J Clin Ultrasound. 2022 Jan;50(1):138-147. doi: 10.1002/jcu.23081. Epub 2021 Oct 14. J Clin Ultrasound. 2022. PMID: 34647631 Review.

7

A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry.

Ray M, Castaigne JG, Zang A, Patel A, Hancock E, Brighton N, Bachy E. Ray M, et al. Among authors: zang a. Adv Ther. 2024 Nov;41(11):4282-4298. doi: 10.1007/s12325-024-02971-1. Epub 2024 Sep 24. Adv Ther. 2024. PMID: 39316290

8

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.

Zhang J, Du Y, Meng Y, Liu X, Mu Y, Liu Y, Shi Y, Wang J, Zang A, Gu S, Liu T, Zhou H, Guo H, Xiang S, Zhang X, Wu S, Qi H, Li M, Hu X. Zhang J, et al. Among authors: zang a. NPJ Precis Oncol. 2024 Sep 12;8(1):200. doi: 10.1038/s41698-024-00687-7. NPJ Precis Oncol. 2024. PMID: 39266619 Free PMC article.

9

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Bardia A, et al. J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920. Online ahead of print. J Clin Oncol. 2024. PMID: 39265124

10

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.

Long J, Li X, Wu L, Yu G, Zang A, Zhao Y, Shi J, Nie L, Zhao X, Fang J. Long J, et al. Among authors: zang a. Cancer Med. 2024 Sep;13(17):e70059. doi: 10.1002/cam4.70059. Cancer Med. 2024. PMID: 39225504 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters